A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

NCT01516918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG: VX-222
DRUG: telaprevir
DRUG: ribavirin
BIOLOGICAL: peginterferon-alfa-2a

Sponsor

Vertex Pharmaceuticals Incorporated